Pharmaceutical Administration and Regulations in Japan - Nihs

More documents

Recommendations

Info

$Allergies to cross-reactive plant proteins. Latex-fruit ... - NIHS$

trial, or the director of the medical institutions involved. • When the trial is completed or discontinued, the results obtained must be compiled in a clinical trial report. When the person conducting the clinical trial learns that the study results collected from the trial concerned were not attached to the application form as application data, this fact and the reason for it must be notified in writing to the directors of the medical institutions performing the trial. • Records related to the clinical trial must be retained for the specified period. Chapter 4: Standards for conduct of clinical trials (Articles 27 to 55) Provisions to be followed by the medical institutions performing clinical trials scientifically and ethically 1) Provisions concerning the Institutional Review Boards (IRB) (Articles 27 to 34) • An Institutional Review Board (IRB), which should meet the requirements specified in Article 28, must be established by the director of the medical institution performing the trial to review and discuss the proper conduct of Pharmaceutical Regulations in Japan: clinical trials and other matters related to the trials. (However, it is not always necessary to establish an IRB in each medical institution performing the study.) • The IRB must review the ethical and scientific appropriateness of the clinical trial subject to review on the basis of the documents specified in Article 32, and state its opinion. • The person establishing the IRB must keep records of meetings and prepare a summary and retain these documents for set periods such as 3 years after completion of the clinical study. The standard operating procedures, list of members, and summary of meeting records prepared for the IRB must be made public. On the PMDA webpage (http://www.pmda.go.jp), the name of the IRB, the name of the person establishing the IRB, the address, and webpage address must be recorded to create an environment that facilitates acquisition of study-related information by clinical study collaborators and keeps a wider public informed (Notification No. 1001013 of the 2011-3 - 103 -
PFSB dated October 1, 2008 and Office Communication dated April 2, 2009). • The director of the medical institution performing the study must heed the opinions of the IRB concerning whether it is appropriate or not to perform the clinical study in the medical institution concerned. • The medical institution is not allowed to conduct a clinical trial when the opinion of the IRB is that it is not appropriate to conduct the trial. • When it is impracticable to organize an IRB for a planned trial at each institution, alternative IRB may be selected from other IRBs inside or outside the institution in the judgment of the director of medical institution. • IRB may disclose information related to IRB review to enhance the level of transparency and secure quality of its review activities. 2) Provisions related to medical institutions performing clinical trials (Articles 35 to 41) • Medical institutions performing clinical trials must have the facilities and personnel to Pharmaceutical Regulations in Japan: undertake adequate clinical observations and laboratory testing, and they must be able to take the measures required when emergencies arise among the trial subjects. • The director of the medical institution performing the trial must prepare SOP for work related to the trial, and take the necessary measures so that the clinical trial is conducted properly and smoothly in compliance with the trial protocol and the SOP. • The director of the medical institution performing the trial must cooperate with monitoring or audits by the sponsor or the person conducting the clinical trial and review by the IRB. • The director of a medical institution must appoint a person or persons to carry out trial-related clerical work. 3) Provisions related to investigators (Articles 42 to 49) • The investigator must have sufficient clinical experience to be able to conduct the trial properly. • The investigator must select the trial subjects in accordance with the objectives of the trial from the ethical and scientific standpoints. 2011-3 - 104 -
Page 1 and 2:
2011.3 INFORMATION IN ENGLISH ON JA
Page 3 and 4:
Table of Contents CHAPTER 1 ···
Page 5 and 6:
4.1 GMP Compliance Reviews ····
Page 7 and 8:
TABLE 3 DATA TO BE SUBMITTED WITH A
Page 9 and 10:
eliability of application data. Fol
Page 11 and 12:
3) Control of household products co
Page 13 and 14:
health care information-processing
Page 15 and 16:
eevaluation of gastrointestinal dru
Page 17 and 18:
contribution to drug research and d
Page 19 and 20:
Ministry of Health, Labour, and Wel
Page 21 and 22:
Committee on Japanese Pharmacopoeia
Page 23 and 24:
CHAPTER 2 Pharmaceutical Laws and R
Page 25 and 26:
11) (License standards, restriction
Page 27 and 28:
of approvals and licenses, approval
Page 29 and 30:
2) Classification according to hand
Page 31 and 32:
(3) Quasi-drug marketing business l
Page 33 and 34:
manufacturer submits an MF registra
Page 35 and 36:
(4) On-site surveys for accreditati
Page 37 and 38:
y testing facilities for nonclinica
Page 39 and 40:
Implementation of Clinical Studies
Page 41 and 42:
December 21, 2005. Based on this La
Page 43 and 44:
Activities Encouraging Illicit Cond
Page 45 and 46:
(7) General review conference (main
Page 47 and 48:
diseases, a decision must be made w
Page 49 and 50:
and use of drugs for pediatric use
Page 51 and 52:
codevelopment group and requirement
Page 53 and 54:
January 28, 2011 entitled “Issuan
Page 55 and 56:
pharmaceutical excipients, physicoc
Page 57 and 58:
application review of raw materials
Page 59 and 60: half of the 1980s and there were al
Page 61 and 62: Patent right 1 Patent right 2 Calcu
Page 63 and 64: Foreign manufacturer with manufactu
Page 65 and 66: Table. 1 List of Main Controlled Su
Page 67 and 68: Table. 2 Divisions of the Pharmaceu
Page 69 and 70: acceptance of the data is condition
Page 71 and 72: p) Consultations on compliance with
Page 73 and 74: http://www.pmda.go.jp/topics/file/
Page 75 and 76: Approval of Manufacturing/Marketing
Page 77 and 78: Summary of biopharmaceutics and ass
Page 79 and 80: 1998 and partial revision by Office
Page 81 and 82: evised or established concerning ph
Page 83 and 84: are performed on the basis of the G
Page 85 and 86: Pharmaceuticals (ICH S2B) (Notifica
Page 87 and 88: Quality Assurance Units Chapter 3 (
Page 89 and 90: y made to Notification No. 813 of t
Page 91 and 92: international harmonization of appr
Page 93 and 94: clinical exploration and developmen
Page 95 and 96: the primary objective of exploring
Page 97 and 98: dose not exceeding 1/100 of the dos
Page 99 and 100: must be analyzed precisely and obje
Page 101 and 102: (21) Structure and Content of Clini
Page 103 and 104: approved drugs and post-marketing c
Page 105 and 106: specified in the ICH guidelines (IC
Page 107 and 108: standards for the sponsoring of cli
Page 109: management of clinical trials (Arti
Page 113 and 114: trial sponsors (Article 59). Howeve
Page 115 and 116: e judged by personnel of the qualit
Page 117 and 118: standards, the Minister of Health,
Page 119 and 120: esults thereof. * Manufacturer, etc
Page 121 and 122: is clear that the items relating to
Page 123 and 124: carries out the duties set forth be
Page 125 and 126: in the two countries. These mutual
Page 127 and 128: PMSB dated February 22, 2000), Guid
Page 129 and 130: Information on approval reviews for
Page 131 and 132: Nonclinical studies Clinical studie
Page 133 and 134: (Table 3) Drug classification syste
Page 135 and 136: (Table 4) Drug classification syste
Page 137 and 138: Module 2 2.3: Quality overall summa
Page 139 and 140: Step 5* Q1A(R2) Q1B Q1C Q1D Q1E Q2
Page 141 and 142: Step 5* E1 Step 4* E2A Code E2B(M)
Page 143 and 144: 1998. Furthermore, a new guideline,
Page 145 and 146: supervisor, quality assurance super
Page 147 and 148: work is required and retention of c
Page 149 and 150: prepared, reported in writing and r
Page 151 and 152: etain these reports. [5] The safety
Page 153 and 154: egard to results of clinical studie
Page 155 and 156: surveyed, analytical method and oth
Page 157 and 158: marketers’ compliance surveys by
Page 159 and 160: approval (known or unknown). g) Ser
Page 161 and 162:
Information about adverse drug reac
Page 163 and 164:
6.2 Periodic Safety Reports (Articl
Page 165 and 166:
Reexamination is based on submissio
Page 167 and 168:
Post-marketing surveillance (PMS) s
Page 169 and 170:
Planning of early post-marketing su
Page 171 and 172:
(MHLW) (PMDA [KIKO]) Selection of r
Page 173 and 174:
and the Role of the Regulatory Auth
Page 175 and 176:
which they are entered in package i
Page 177 and 178:
the beginning of the Precautions wh
Page 179 and 180:
1.5 Entries for Biological Products
Page 181 and 182:
2.2 Pharmaceutical Interview Forms
Page 183 and 184:
the basis of an order issued in cas
Page 185 and 186:
the journals of the Japan Medical A
Page 187 and 188:
Labeling requirements of excipients
Page 189 and 190:
No PMDA safety assessment team (5 t
Page 191 and 192:
CHAPTER 6 Health Insurance Programs
Page 193 and 194:
coverage was changed to 80% of medi
Page 195 and 196:
OF DRUGS LISTED IN THE NHI DRUG PRI
Page 197 and 198:
(excluding those in the JP) in the
Page 199 and 200:
0212-(6) of the Health Policy Burea
Page 201 and 202:
1998 Sept. 1997 5% 2% (Long listed
Page 203 and 204:
Table 9. Requirements for Applying
Page 205 and 206:
Within 60 days as a rule or 90 days
Page 207 and 208:
Index 1 15-Day reports (ADR) ......
Page 209 and 210:
Quality Standards and Government Ce
Page 211 and 212:
(MHLW) Office of New Drug III (PMDA
Page 213 and 214:
Specified biological products .....
Page 215 and 216:
(Chapter 4) Kazuyo MARUCHI Product
show all

Pharmaceutical Administration and Regulations in Japan - Nihs

Create successful ePaper yourself

Delete template?

Save as template?